Arvinas, Inc. (ARVN) shares soared 9.2% in the last trading session to close at $32.73. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 20.2% gain over the past four weeks.The stock rallied, driven by optimism over the company’s ongoing pipeline progress. Arinivas is currently evaluating its lead candidate, vepdegestrant, in two late-stage studies — VERITAC-2 and VERITAC-3 — as a monotherapy to treat second-line breast cancer and ...